A Phase II Trial of Panobinostat, a Histone Deacetylase Inhibitor, in the Treatment of Patients with Refractory Metastatic Renal Cell CarcinomaJohn D. Hainsworth, Howard A. Burris, Edward Arrowsmith et al.|Cancer Investigation|2011Cited by 87
Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment of Patients with Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy: Toxicity Comparison of Two Dose SchedulesJesús G. Berdeja, Ian W. Flinn, James Essell et al.|Blood|2012Cited by 11
Phase <scp>II</scp> study of bendamustine, bortezomib and dexamethasone (<scp>BBD</scp>) in the first‐line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapyJesús G. Berdeja, Ian W. Flinn, Todd M. Bauer et al.|British Journal of Haematology|2017Cited by 8
Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment of Patients (Pts) with Multiple Myeloma (MM) Who Are Not Candidates for High Dose ChemotherapyJesús G. Berdeja, Ian W. Flinn, Ralph V. Boccia et al.|Clinical Lymphoma Myeloma & Leukemia|2015Cited by 2